We did, however, see strong associations of two pretreatment tumor features–IL-8 signature and Consensus stroma-rich subtype–with improved response to chemo-immunotherapy versus a previously published study where patients received atezolizumab without chemotherapy (ABACUS), suggesting that these features are associated with the added response benefit of incorporating neoadjuvant chemotherapy with immunotherapy. This evidence concerns the gene CXCL8 and neoplasm.